Boehringer accesses untouched cancer targets through Enara deal

Boehringer’s reach into the most cutting-edge science continues through its new deal with Enara to access dark antigen targets for cancer immunotherapies. 

Boehringer Ingelheim GmbH teamed up with Enara Bio Ltd. to research and develop novel immunotherapies for up to three types of lung and gastric cancers using Enara’s Dark Antigen Discovery platform. Boehringer has the option to license dark antigens discovered and validated by Enara in exchange for an undisclosed upfront payment, research and preclinical milestones and a licensing fee for each of the three tumor types. Enara is also eligible for over €876 million ($1.1 billion) in clinical, regulatory and commercial milestones. ...